TOVX | tickerfilter.com

Fundamental analysis

17%

Profitability 0%

Dept financing 37%

Liquidity 50%

Performance 20%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.85%

1 Month

-17.87%

3 Months

-26.90%

6 Months

-35.76%

1 Year

141.90%

2 Year

55.88%

Key data

Stock price

$1.06

P/E Ratio

0.00

DAY RANGE

$1.02 - $1.08

EPS

-$3.30

52 WEEK RANGE

$0.11 - $7.15

52 WEEK CHANGE

$140.91

MARKET CAP

4.869 M

YIELD

N/A

SHARES OUTSTANDING

1.005 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

1.15

PUBLIC FLOAT

AVERAGE 10 VOLUME

$19,396

AVERAGE 30 VOLUME

$22,492

Company detail

CEO: Steven A. Shallcross
Region: US
Website: therivabio.com
Employees: 20
IPO year: 2012

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Synthetic Biologics, Inc. develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade intravenous beta-lactam antibiotics in gastrointestinal (GI) tract. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.

TOVX - Theriva Biologics, Inc.